Subscribe To

Price Alert Latest News Economic Calendar News

KALA / Why Is Kala Pharmaceuticals (KALA) Stock Soaring 240%?

Amid another soft performance for the benchmark equities index, rare-eye disease specialist Kala Pharmaceuticals (NASDAQ: KALA ) lit up the overcast sky with a stunning triple-digit performance. Yesterday afternoon, the company announced that it received approval by the Food and Drug Administration (FDA) for its investigational new drug (IND) application centered on its flagship therapeutic candidate KPI-012. Read More

Demo Live Account See Partner Details

Content Topics

KALA

Pharmaceuticals

Stock

Soaring

240 kala

Posted: Dec 28 2022, 13:14

Author Name: InvestorPlace

KALA News

By Zacks Investment Research
April 13, 2023

KALA Up on Fast Track Designation to Lead Ocular Candidate

KALA gets Fast Track Designation from the FDA for lead candidate KPI-012 to treat persistent corneal epithelial defects.

By Zacks Investment Research
March 24, 2023

Wall Street Analysts Predict a 213.6% Upside in Kala Pharma (KALA): Here's What You Should Know

The mean of analysts' price targets for Kala Pharma (KALA) points to a 213.6% upside in the stock. While this highly sought-after metric has not prove

By GlobeNewsWire
March 8, 2023

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

ARLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to

By Zacks Investment Research
March 6, 2023

KALA Q4 Loss Wider Than Expected, Pipeline Remains in Focus

Kala's Q4 earnings miss estimates. Its shares rise in pre-market trading on Mar 6.

By Zacks Investment Research
February 22, 2023

Kala Pharmaceuticals (KALA) Flat As Market Sinks: What You Should Know

Kala Pharmaceuticals (KALA) closed the most recent trading day at $11.90, making no change from the previous trading session.

By Seeking Alpha
January 19, 2023

Kala Pharma: Rare Eye Disease Biotech Lottery Ticket Based On Stem Cell Platform

FDA Accepted IND Filing for the company to initiate a phase 2b study using KPI-012 for the treatment of patients with the persistent corneal epithelia

By MarketBeat
January 11, 2023

Kala Pharmaceuticals Up 400% In The Past Month, What's Next?

Kala pharmaceuticals underwent a massive rally over the past few days, and by all indications, the stock price is now headed toward a bottom.

By Market Watch
December 30, 2022

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Shares of Kala Pharmaceuticals Inc. KALA, +39.53% have rocketed higher in for three-straight sessions, toward a more-than 8-fold gain, since the bioph

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.